Compare Edwards Lifesciences Corporation Common Stock (EW) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edwards Lifesciences Corporation Common Stock vs L3Harris Technologies Inc — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $84.24 (market cap $48.56B), while L3Harris Technologies Inc trades at $237.1 (market cap $44.12B). The key difference: Edwards Lifesciences Corporation Common Stock and L3Harris Technologies Inc are close in size by market cap, and L3Harris Technologies Inc pays a 2.11% dividend while Edwards Lifesciences Corporation Common Stock pays none. Which is the better fit depends on your goals.
| EW | LHX | |
|---|---|---|
Market Cap | $48.56B | $44.12B |
Volume | 6,520,488 | 1,202,852 |
Sector | Health | Industrials |
52-Week High | $95.18 | $378.48 |
52-Week Low | $72.65 | $233.63 |
Enterprise Value | $45.01B | $54.56B |
Typical Hold Time | — | 55 Days |
Dividend Yield | — | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
LHX trades at $233.63, down 1.79% today, with a bearish technical signal despite strong fundamentals. The company reported three consecutive quarterly EPS beats, with Q3 2026 results pending. Recent contract wins include a $6 billion THAAD propulsion deal with Lockheed Martin. Valuation metrics show a P/E of 23.6 and P/S of 1.92, with improving profit margins reaching 7.34% in 2025.
Analyst consensus remains strongly bullish with a $340 price target (45% upside), though legal investigations pose near-term risk. The stock offers solid revenue growth and dividend income, but investors should monitor the multiple law firm investigations and technical weakness. Long-term prospects appear favorable given defense budget tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Edwards Lifesciences Corporation Common Stock
Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
